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Conophylline (CNP) has various biological activities, such as insulin production. A recent study iden-
tiﬁed ADP-ribosylation factor-like 6-interacting protein 1 (ARL6ip1) as a direct target protein of CNP.
In this study, we revealed that ARL6ip1 is a three-spanning transmembrane protein and determined
the CNP-binding domain of ARL6ip1 by deletion mutation analysis of ARL6ip1 with biotinyl-amino-
CNP. These results suggest that CNP is expected to be useful for future investigation of ARL6ip1 func-
tion in cells. Because of the anti-apoptotic function of ARL6ip1, CNP may be an effective therapeutic
drug and/or a novel chemosensitizer for human cancers and other diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Conophylline (CNP; Fig. 1A), a Vinca alkaloid, was isolated from
leaves of Tavertaemontana divaricate [1]. CNP was later isolated
again from Ervatamia microphylla as a Ras function inhibitor that
induced normal morphology in K-ras-transformed NRK cells [2].
CNP showed anti-tumor activities, such as inhibition of cellular
chemotactic invasion, inducing normal morphology and growth
inhibition in K-ras-transformed cells and cancer cells [3]. More-
over, CNP was found to induce pancreatic b-cell differentiation
from pancreatic exocrine carcinoma cells [4], and it lowered the
blood level of glucose in type-2 diabetes model mice [5]. Therefore,
CNP is expected to be applied to b-cell regeneration chemotherapy.
In the course of in vivo study, CNP was also found to exert anti-ﬁ-
brotic actions in pancreatic islets in type-2 diabetes Goto-Kakizaki
rats [6].
A recent study identiﬁed ADP-ribosylation factor-like protein 6-
interacting protein 1 (ARL6ip1) as a direct target protein of CNP byusing CNP-linked latex nano-beads [7]. ARL6ip1 was ﬁrst identiﬁed
as an interacting molecule of ARL6, a member of the ARL subfamily
of small GTPases, by use of the yeast two-hybrid system [8]. AR-
L6ip1 is an integral transmembrane protein with four predicted
transmembrane regions. It consists of 203 amino acids and local-
izes to the endoplasmic reticulum (ER) membrane [9]. The C-ter-
minal sequence of ARL6ip1, KKNE, corresponds to the KKXX
sequence commonly found in the C-terminal region of ER mem-
brane proteins, which might function as an ER retention motif
[9,10].
It was reported that overexpression of ARL6ip1 in HT1080 cells
exhibits anti-apoptotic activity from multiple apoptotic inducers,
caused by inhibition of caspase-9 activity [9]. It was also demon-
strated that ARL6ip1 interacts with ARL6ip5 and promotes
EAAC1-mediated glutamate transport activity [11]. Since ARL6,
with which ARL6ip1 interacts, is likely to be engaged in intracellu-
lar trafﬁcking, ARL6ip1 could also regulate intracellular trafﬁcking
pathways in the ER membrane, but its cellular functions are not
fully deﬁned.
In this study, we determined the topological structure of AR-
L6ip1 in cells by redox-sensitive luciferase assay, a rapid and re-
cently reported conventional topological assay, using Gaussia
luciferase (Gluc) [12]. In addition, we identiﬁed the important re-
gion of ARL6ip1 for interacting with CNP. Taken together, it is sug-
gested that CNP is expected to aid in the further clariﬁcation of the
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Fig. 1. Structure of CNP and BCNP and primary structure of ARL6ip1. (A) Structure of CNP and BCNP. (B) Putative transmembrane regions (hatched bars; TM 1–4) and non-
transmembrane regions (open boxes; Site 1–4) of ARL6ip1. A black area indicates the KKNE sequence. (C) Amino acid sequence of human ARL6ip1. Enclosed areas indicate
putative transmembrane regions. The residues pointed by arrows indicate the C-terminally Gluc-attached position. For examples, V29 and P64 mean that Gluc was inserted
between Val29 and Met30 and Pro64 and Ser65 of human ARL6ip1, respectively. P64⁄ means (M1-P64)-fused Gluc.
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negatively regulates apoptosis induced by various stimuli [9], our
results might provide a rationale to combine CNP and antitumor
drugs in cancer therapy.
2. Materials and methods
2.1. Materials
CNP was isolated from the leaves of E. microphylla as reported
previously [2]. Biotinyl-amino-CNP (BCNP; Fig. 1A) was synthe-
sized from isolated CNP according to our previous report [7]. Syn-
thesized BCNP was conﬁrmed by NMR and ESI-MS.
2.2. Construction of plasmid vectors, cell culture and transfection,
redox-sensitive luciferase assay and b-galactosidase assay, in vitro
binding assay, and Western blotting
The protocols used for the construction of plasmid vectors, cell
culture, transfection, redox-sensitive luciferase assay and b-galac-tosidase assay, in vitro binding assay, and Western blotting are
indicated in Supplementary materials and methods [12–18].
3. Results
3.1. Determination of ARL6ip1 topology using redox-sensitive assay
The predicted transmembrane regions (TMs) of ARL6ip1 ob-
tained in the UniProt database (http://www.uniprot.org/) were
shown in Fig. 1B. Although it has been suggested that ARL6ip1
has four predicted transmembrane regions (TM 1–4) and four
non-transmembrane regions (Site 1–4), its topology is still un-
known. To determine the topology of ARL6ip1, we performed a re-
dox-sensitive luciferase assay [12]. Gluc functions as a redox
reporter that requires an oxidative environment for its activity
but does not work under reducing conditions.
To evaluate Gluc activities for the identiﬁcation of ARL6ip1
topology, we constructed a series of Gluc-fused ARL6ip1 proteins
(Fig. 1C). HT1080 cells were transfected with these constructs
along with a control vector encoding b-galactosidase and lysed,
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were measured. The ratio of bioluminescence to b-galactosidase
activity of R189 and E199 was much higher than the others, sug-
gesting that the V29 (Site 1), L37 (Site 1), R90 (Site 3), T99 (Site
3), and A119 (Site 3) fusions are localized in the cytoplasm, while
the R189 (Site 4) and E199 (Site 4) fusions are in the ER lumen
(Fig. 2A). To clarify whether Site 2 of ARL6ip1 is localized in the
cytoplasm or ER, we attached Gluc to the C-terminus of P64 of AR-
L6ip1 (P64) and the C-terminus of a.a. 1–64 of ARL6ip1 (P64⁄). The
results suggests that Site 2 is localized in the cytoplasm and ER lu-
men data from P64 and P64⁄, respectively, probably because Site 2
consists of only three amino acids and P64 fails to attain proper
conformation caused by steric hindrance of Gluc. These results
indicate that Site 1 and Site 3 are localized in the cytoplasm, and
Site 2 and Site 4 are localized in the ER lumen. It also suggests that
ARL6ip1 is a three-spanning transmembrane protein (Fig. 2C).
3.2. Identiﬁcation of important region of ARL6ip1 for binding to CNP
To determine which site in ARL6ip1 is essential for interaction
with CNP, we constructed GFP-fused ARL6ip1 mutants, as shown(A) 
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Fig. 2. Determination of topology of human ARL6ip1. (A and B) The bioluminescence/ab
cytosol are displaced separately in two groups, as indicated with two straight lines. Data
gray area indicates ER membrane.in Fig. 3A. HEK 293T cells that were transfected with these con-
structs were lysed and incubated with NeutrAvidin bead-bound
BCNP. GFP-ARL6ip1 (D1–41), as well as GFP-ARL6ip1 (WT), was
co-precipitated with NeutrAvidin bead-bound BCNP; however,
GFP-ARL6ip1 (D1–86) and (D1–133) were not (Fig. 3B), suggesting
that the a.a. 42–86 region of ARL6ip1 is essential for the interaction
with CNP.
For further analysis, we constructed a GFP-tagged ARL6ip1 dele-
tion mutant lacking a.a. 42–86 (D42–86) and a GFP-tagged trun-
cated a.a. 42–133 ARL6ip1 fragment with a KKNE sequence at its
C-terminus (42–133 + KKNE) (Fig. 3A). Fig. 3C shows that GFP-AR-
L6ip1 (D42–86) exhibits very weak binding ability to BCNP as com-
pared to WT. Meanwhile, GFP-ARL6ip1 (42–133 + KKNE) binds to
BCNP, but its binding ability is weaker than that of WT. These re-
sults indicate that TM 1 and TM 2 are essential for the interaction
of ARL6ip1 with CNP, but they are not sufﬁcient for CNP binding.
From the results of the topological analysis of ARL6ip1 and the
in vitro binding assay, we assume that CNP binds to Site 3, a.a.
87–133, of ARL6ip1, because it is generally considered that com-
pounds bind to non-transmembrane regions of target proteins.
Since the binding capacity of GFP-ARL6ip1 (42-133 + KKNE) with4 5 6 
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Fig. 3. Determination of important region of ARL6ip1 for binding to CNP. (A) Schematic illustrations of GFP-fused ARL6ip1 deletion mutants. (B and C) Cells were transfected
with the vectors encoding GFP-ARL6ip1 or deletion form of ARL6ip1 for 30 h. The total cell lysates were extracted, precleared with equilibrated NeutrAvidin beads for 2 h, and
mixed with NeutrAvidin bead-bound BCNP for 2 h at 4 C. A portion of equilibrated lysates was collected as ‘‘Input’’. After washing, the proteins that interacted with
NeutrAvidin bead-bound BCNP were eluted with the sample buffer. BCNP-interacted ARL6ip1 was detected by Western blotting using anti-GFP antibody.
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(D42–86), as shown in Fig. 3C, transmembrane regions would be
important for forming Site 3 with a stable loop structure that al-
lows it to interact with CNP.
4. Discussion
In this study, we have characterized the topological structure of
ARL6ip1 and the CNP-binding region of ARL6ip1. Although ARL6ip1
had been proposed to be a four-spanning transmembrane protein,
we showed that ARL6ip1 is a three-spanning transmembrane pro-
tein with the N-terminus and C-terminus facing the cytosol and ER
lumen, respectively (Fig. 1 and 2). In addition, to identify the region
that is critical for the interaction of ARL6ip1 with CNP, we synthe-
sized BCNP and performed an in vitro binding assay. Deletion
mutation analysis of GFP-ARL6ip1 revealed that the a.a. 42–86 re-
gion of ARL6ip1 is essential for the interaction of CNP with ARL6ip1
(Fig. 3). Further analyses revealed that the only the a.a. 42–86 re-
gion is not sufﬁcient for CNP binding (Fig. 3). From the topological
analysis of ARL6ip1, we assume that the direct CNP binding site is
Site 3 (87–113 a.a.), while the TM regions, such as TM 1 and TM 2,would be important for forming Site 3 with a stable loop structure
that allows it to interact with CNP.
Although the a.a. 42–86 region (TM 1, Site 2, and TM 2) of AR-
L6ip1 is important for the interaction of ARL6ip1 with CNP, it con-
tains only a 3-a.a. non-TM region: Asp63-Pro64-Ser65. To
investigate whether Site 2 is required for the interaction with
CNP, we constructed three Site 2 mutant expression vectors
(DPA, NPA, and SSS). All mutants were bound to NeutrAvidin
bead-bound BCNP, as well as wild-type (DPS) (data not shown).
These results suggest that the sequence of Site 2 is not important
for the interaction with CNP, while TM 1 and TM 2 would be re-
quired for the interaction.
ARL6ip1 consists of the KKNE sequence at its C-terminus, which
conforms to the KKXX motif commonly found in ER membrane
proteins, mediating their retention in the ER. To investigate
whether the C-terminal KKNE sequence also functions as an ER
retention signal, we constructed Gluc mutants that were localized
to various organelles (Fig. S1). Gluc (SP), in which the signal pep-
tide of Gluc was deleted, was localized in the cytosol, while full-
length Gluc was localized in the ER lumen and extracellular space,
and Gluc+KDEL, known as the ER retention a.a. sequence, was
3660 M. Kuroda et al. / FEBS Letters 587 (2013) 3656–3660localized in the ER. We also constructed Gluc mutants, including
Gluc+KKNE and Gluc (SP)+KKNE (Fig. S1). The assay shows that
Gluc+KKNE is localized in the ER lumen and extracellular space,
and Gluc (SP)+KKNE is localized in the cytosol, suggesting that
the C-terminal KKNE sequence does not function for retention in
the ER lumen. It has been reported that the cytoplasmic C-terminus
di-lysine motifs are important for Golgi-to-ER retrieval and capture
by coatomers and packaged into vesicles in their ER–Golgi trafﬁck-
ing [19,20]; however, the KKNE motif in ARL6ip1 may not function
as an ER retrieval motif.
In summary, this is the ﬁrst report of the topological structure
of human ARL6ip1. Our results suggest that, contrary to the puta-
tive structure with four-transmembrane-spanning domains, AR-
L6ip1 is three-spanning transmembrane protein. Moreover, we
demonstrated that Site 3 of ARL6ip1 is an essential region for inter-
action with CNP; besides, TM regions would be also important for
the stabilization of Site 3. The results provide us to develop a novel
screening system for the identiﬁcation of small-molecule inhibi-
tors and/or peptides that interact with the speciﬁc region of AR-
L6ip1. The role of each site and TM for ARL6ip1 function might
be revealed by the obtained inhibitors. Moreover, because CNP
showed anti-tumor, anti-diabetes, and anti-ﬁbrotic actions, our
ﬁndings might provide new clues for understanding the role of AR-
L6ip1 for these diseases. Furthermore, CNP augmented apoptosis in
human cancer cell lines that was induced by treatment with drugs,
such as brefeldin A (data not shown); thus, CNP may be a novel
chemosensitizer for human cancers.
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